{
    "id": 25765,
    "fullName": "PLCG2 R665W",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PLCG2 R665W lies within the SH2 2 domain of the Plcg2 protein (UniProt.org). R665W confers a gain of function to Plcg2, as indicated by increased calcium flux, activation of ERK, and increased basal activity and sensitivity to Rac stimulation in culture, and is associated with resistance to BTK inhibition (PMID: 25972157, PMID: 27542411).",
            "references": [
                {
                    "id": 7186,
                    "pubMedId": 25972157,
                    "title": "Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25972157"
                },
                {
                    "id": 7583,
                    "pubMedId": 27542411,
                    "title": "The Phospholipase C\u03b32 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542411"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5336,
        "geneSymbol": "PLCG2",
        "terms": [
            "PLCG2",
            "APLAID",
            "FCAS3",
            "PLC-gamma-2",
            "PLC-IV"
        ]
    },
    "variant": "R665W",
    "createDate": "11/28/2016",
    "updateDate": "06/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 101879,
        "transcript": "NM_002661",
        "gDna": "chr16:g.81912655C>T",
        "cDna": "c.1993C>T",
        "protein": "p.R665W",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, treatment with EHT 1864 decreased Plcg2 activity in cells expressing PLCG2 R665W in culture, suggesting that Rac inhibition may be a potential treatment approach for tumors harboring Imbruvica (ibrutinib)-resistant PLCG2 mutations (PMID: 27542411).",
            "molecularProfile": {
                "id": 26844,
                "profileName": "PLCG2 R665W"
            },
            "therapy": {
                "id": 5223,
                "therapyName": "EHT 1864",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7583,
                    "pubMedId": 27542411,
                    "title": "The Phospholipase C\u03b32 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542411"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9427,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PLCG2 R665W was identified in patients that relapsed after treatment with Ibruvica (ibrutinib), and studies in cell lines expressing PLCG2 R665W supported a role in mediating Ibruvica (ibrutinib) resistance (PMID: 25972157).",
            "molecularProfile": {
                "id": 26844,
                "profileName": "PLCG2 R665W"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7186,
                    "pubMedId": 25972157,
                    "title": "Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25972157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26844,
            "profileName": "PLCG2 R665W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 101879,
            "transcript": "NM_002661",
            "gDna": "chr16:g.81912655C>T",
            "cDna": "c.1993C>T",
            "protein": "p.R665W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}